{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:25:31Z","timestamp":1779395131984,"version":"3.53.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaccas.2025.103953","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T22:25:55Z","timestamp":1752618355000},"page":"103953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Apparent Nonresponse to PCSK9 Inhibition in a Patient With Heterozygous Familial Hypercholesterolemia Due to PCSK9 Gene Duplication"],"prefix":"10.1016","volume":"30","author":[{"given":"Mustansir","family":"Pindwarawala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3686-3807","authenticated-orcid":false,"given":"Liam R.","family":"Brunham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccas.2025.103953_bib1","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccas.2025.103953_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaccas.2025.103953_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaccas.2025.103953_bib4","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.cjca.2018.07.479","article-title":"Whole-gene duplication of PCSK9 as a novel genetic mechanism for severe familial hypercholesterolemia","volume":"34","author":"Iacocca","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jaccas.2025.103953_bib5","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccas.2025.103953_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccas.2025.103953_bib7","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccas.2025.103953_bib8","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccas.2025.103953_bib9","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacl.2018.05.017","article-title":"Case reports of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition nonresponse","volume":"12","author":"Saeed","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jaccas.2025.103953_bib10","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaccas.2025.103953_bib11","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccas.2025.103953_bib12","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia","volume":"74","author":"Koren","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccas.2025.103953_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2485","article-title":"Diagnosing resistance to a proprotein convertase subtilisin\/kexin type 9 inhibitor","volume":"168","author":"Shapiro","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaccas.2025.103953_bib14","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccas.2025.103953_bib15","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cjca.2018.08.027","article-title":"A novel cause of familial hypercholesterolemia: PCSK9 gene duplication","volume":"34","author":"Paquette","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jaccas.2025.103953_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.05.013","article-title":"Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia","volume":"304","author":"Lau","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaccas.2025.103953_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100012","article-title":"Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol","volume":"1","author":"Warden","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jaccas.2025.103953_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.06.405","article-title":"Dual therapy with inclisiran and evolocumab in a heterozygous FH patient while on maximum statin and ezetimibe dose to achieve LDL targets","volume":"379","author":"Gingell","year":"2023","journal-title":"Atherosclerosis"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084925007338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084925007338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T22:26:50Z","timestamp":1752618410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084925007338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":18,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2666084925007338"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2025.103953","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apparent Nonresponse to PCSK9 Inhibition in a Patient With Heterozygous Familial Hypercholesterolemia Due to PCSK9 Gene Duplication","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2025.103953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103953"}}